Clinical Trial Update: Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating sodium stibogluconate in myelodysplastic syndromes and acute myeloid leukemia with specific p53 mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Sodium stibogluconate (sodium stibogluconate)

Snippet

Sponsor: First Affiliated Hospital of Jinan University | Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | Status: UNKNOWN